Literature DB >> 6198397

Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.

H Fujiwara, Y Moriyama, T Suda, T Tsuchida, G M Shearer, T Hamaoka.   

Abstract

The present study was designed to investigate the generation of trinitrophenyl (TNP)-reactive helper T cell activity potent enough to induce the regression of a syngeneic tumor; this occurs by augmenting antitumor-specific immunity through T-T cell interaction. Mice whose skin was painted with trinitrochlorobenzene (TNCB) exhibited a variety of anti-TNP T cell responses, including delayed-type hypersensitivity (DTH) and cytotoxic T cell responses, as well as helper T cell activity. Pretreatment of C3H/He mice with TNP-conjugated copolymer of D-glutamic acid and lysine (TNP-D-GL) or cyclophosphamide, which have been shown, respectively, to inactivate TNP-specific suppressor T cells or suppressor T cells in general, exhibited a slight or marginal augmentation of DTH and cytotoxic potentials when tested 5 wk after TNCB painting. In contrast, the same pretreatment regimens induced an appreciably amplified generation of anti-TNP helper T cell activity. This amplified TNP-helper T cell activity was demonstrated to enhance cytotoxic responses to antigens other than TNP in an antigen-nonspecific way. In fact, such helper T cells enhanced antitumor CTL responses when co-cultured with spleen cells from syngeneic X5563 plasmacytoma-bearing mice in the presence of TNBS-modified X5563 tumor cells. This amplified TNP-helper cell system was utilized for its immunotherapeutic potential. When TNCB was injected into X5563 tumor mass of syngeneic C3H/He mice in which the amplified TNP-helper T cell activity had been generated, an appreciable number of growing tumors was observed to regress. This contrasted with the low incidence of tumor regression observed in mice in which TNP-helper activity had been induced by TNCB painting without inactivation of suppressors. Thus, the present model provides an effective immunotherapeutic manipulation for eliciting enhanced in vivo tumor regression, and emphasizes a role of helper T cells in augmentation of syngeneic tumor immunity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198397

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Enhancement of immunity against RSV-induced sarcomas by generation of hapten-reactive helper T lymphocytes.

Authors:  P M Comoglio; M Prat; S Bretti
Journal:  Immunology       Date:  1985-02       Impact factor: 7.397

2.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.

Authors:  H Sano; A Kosugi; S Sano; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  The generation of tumor-specific in vivo protective immunity in the tumor mass from mice rendered tolerant to tumor antigens.

Authors:  S Sano; Y Izumi; S Sugihara; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  Studies on the recovery from tolerance to tumor antigens. II. Accelerated recovery of tumor-specific effector T cells in tolerant mice by applying T-T cell interaction mechanism.

Authors:  S Sato; H Fujiwara; A Kosugi; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 5.  The role of contrasuppression in tumor regression.

Authors:  P M Flood; A Friedman; J Freedman; B Horvat; P Reuter; W Ptak
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

6.  Evaluation of in vivo and in vitro effectivity of immune defense against a spontaneously arising, nonlymphoid rat tumor. II. T cell response after induction of immunogenicity.

Authors:  M Zöller
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Effect of interleukin-2 on the ex vivo growth of human myeloma cells.

Authors:  D Peest; I de Vries; R Hölscher; R Leo; H Deicher
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  Enhanced tumor susceptibility of immunocompetent mice infected with lymphocytic choriomeningitis virus.

Authors:  M Kohler; B Rüttner; S Cooper; H Hengartner; R M Zinkernagel
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

9.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity.

Authors:  T Hamaoka; Y Takai; A Kosugi; Y Mizushima; J Shima; T Kusama; H Fujiwara
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Plant lectin, ATF1011, on the tumor cell surface augments tumor-specific immunity through activation of T cells specific for the lectin.

Authors:  R Yoshimoto; N Kondoh; M Isawa; J Hamuro
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.